UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Holdings in Kenvue Inc. (NYSE:KVUE)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 22.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 12,281,193 shares of the company's stock after buying an additional 2,288,260 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.64% of Kenvue worth $262,203,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Geneos Wealth Management Inc. purchased a new stake in Kenvue during the fourth quarter worth $29,000. SRS Capital Advisors Inc. raised its position in shares of Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after acquiring an additional 571 shares during the period. Asset Planning Inc acquired a new position in shares of Kenvue in the fourth quarter worth about $42,000. Clarity Asset Management Inc. purchased a new stake in shares of Kenvue during the 4th quarter worth about $45,000. Finally, SBI Securities Co. Ltd. acquired a new stake in shares of Kenvue during the 4th quarter valued at about $46,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue Price Performance

NYSE KVUE traded up $0.14 during mid-day trading on Tuesday, hitting $23.87. The stock had a trading volume of 4,286,100 shares, compared to its average volume of 16,323,860. The firm's 50 day moving average is $23.24 and its 200 day moving average is $22.62. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The stock has a market capitalization of $45.79 billion, a price-to-earnings ratio of 45.03, a PEG ratio of 2.62 and a beta of 1.02. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. The business had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. The company's revenue for the quarter was down 3.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.28 earnings per share. Equities research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th will be issued a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a yield of 3.44%. Kenvue's payout ratio is 149.09%.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Canaccord Genuity Group upped their price target on Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. Barclays boosted their price objective on Kenvue from $22.00 to $23.00 and gave the company an "equal weight" rating in a research report on Monday, May 12th. Redburn Atlantic started coverage on Kenvue in a research report on Thursday, April 10th. They set a "neutral" rating and a $23.50 target price on the stock. Piper Sandler lifted their price target on shares of Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research note on Monday, February 24th. Finally, UBS Group upped their price objective on shares of Kenvue from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Friday, May 9th. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, Kenvue currently has an average rating of "Hold" and a consensus target price of $25.33.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.